for innovative medical applications
Khorionyx is a R&D biomedical company founded in 2003 with the objective of developing innovative medical applications based upon human globin.
Peripheral blood is the most accessible human tissue, from which hemoglobin can be quickly and easily prepared. Globin is the protein derived from human hemoglobin after removal of its red pigment and the only human protein easily available in large quantities.
Globin, a unique biomaterial
Globin implants are made from a pure and well-defined insoluble protein, without any chemical additive. Its autologous or allogenic character guarantees a safe implantation which can be repeated as long as necessary. This makes it particularly attractive as a source of biomaterials.
Like collagen, globin is insoluble in physiological conditions and stays where it is implanted. Insoluble globin can be prepared in the form of injectable pastes, powders, dry sprays, sponges or coatings. A globin implant creates an additional space which is progressively colonized by macrophages and fibroblasts creating new collagen fibres. No residue is left in the repaired tissue after natural degradation of the globin scaffold. In addition, human globin brings other unique properties to develop bioactive implants. Among them, the broad and potent bactericidal properties of the globin implant against Gram+ and Gram- bacteria make possible to keep the implanted area in a sterile environment.
Khorionyx started to develop the aesthetic application of the autologous globin dermal filler for soft tissue augmentation. The corresponding I.N.D. has been granted by FDA in 2009, for a first pilot clinical study in USA. This study has demonstrated the safety and efficacy of the globin dermal filler. This first project opens the way for many other medical applications in significant markets.
Keywords: globin, biomaterial, implant, dermal filler, tissue repair, wound healing, wound care, osteogenesis, hemostasis, polymer network, sealant, drug delivery.
Jean-Louis TAYOT – Khorionyx founder
Jean-Louis TAYOT is a biochemist from INSA Lyon, PhD of the University of Lyon – France
Since 1967, he was part of the R&D division of INSTITUT MERIEUX, now SANOFI PASTEUR, where he developed industrial purification technologies of vaccines, blood and placental products.
From 1987 to 1998 he was the general manager of IMEDEX, a subsidiary of PASTEUR MERIEUX where he conducted the development of several drugs and medical devices
Partnership with GENZYME to extract and purify the placental glucocerebrosidase enzyme to prepare Ceredase® the first therapy of the Gaucher’s disease.
Development of the industrial processes and surgical applications of animal and placental human collagens at the origin of 12 patent families and 4 companies:
Episkin, a subsidiary of L'Oréal, producing human skin models for testing cosmetics;
Symatèse, a subsidiary of Laboratoires Pérouse specialized in biopolymers;
Imedex Biomatériaux, a division of Sofradim/Floréane, now a Medtronic company;
Albiorex, now Regenerative Processing Plant, a Florida based company focused on human placenta derived biologics and collagens.
From 1998 to 2005 he was the general manager of Imedex Biomatériaux.
He founded KHORIONYX in 2003, to personally develop the globin technology and products in collaboration with financial, medical and laboratory partners until 2012.
Credits: Header painting by Jean-Paul HELME